124 related articles for article (PubMed ID: 34655194)
1. IL-10 as an Indicator for Predicting Clinical Progression in Acute Lymphoblastic Leukemia Patients.
Zhang K; Li X; Huang R; Chen C; Hu W
Clin Lab; 2021 Oct; 67(10):. PubMed ID: 34655194
[TBL] [Abstract][Full Text] [Related]
2. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Westbrook CA; Hooberman AL; Spino C; Dodge RK; Larson RA; Davey F; Wurster-Hill DH; Sobol RE; Schiffer C; Bloomfield CD
Blood; 1992 Dec; 80(12):2983-90. PubMed ID: 1467514
[TBL] [Abstract][Full Text] [Related]
4. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.
Iacobucci I; Lonetti A; Paoloni F; Papayannidis C; Ferrari A; Storlazzi CT; Vignetti M; Cilloni D; Messa F; Guadagnuolo V; Paolini S; Elia L; Messina M; Vitale A; Meloni G; Soverini S; Pane F; Baccarani M; Foà R; Martinelli G
Haematologica; 2010 Oct; 95(10):1683-90. PubMed ID: 20534699
[TBL] [Abstract][Full Text] [Related]
5. Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia.
Park HH; Kim M; Lee BH; Lim J; Kim Y; Lee EJ; Min WS; Kang CS; Kim WI; Shim SI; Han K
Ann Clin Lab Sci; 2006; 36(1):7-15. PubMed ID: 16501231
[TBL] [Abstract][Full Text] [Related]
6. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
7. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
8. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
9. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.
Yokota H; Tsuno NH; Tanaka Y; Fukui T; Kitamura K; Hirai H; Osumi K; Itou N; Satoh H; Okabe M; Nakahara K
Leukemia; 2002 Jun; 16(6):1167-75. PubMed ID: 12040449
[TBL] [Abstract][Full Text] [Related]
10. BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy.
Yamada C; Shimomura Y; Kamijyo K; Kanda-Kato M; Yoshioka S; Yamashita D; Ishikawa T
Intern Med; 2021 Oct; 60(19):3149-3153. PubMed ID: 33814500
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of serum NGF level and CD271 expression in patients with acute B lymphoid leukemia].
Han XH; Xu KL; Zeng LY; Li ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1273-6. PubMed ID: 22040987
[TBL] [Abstract][Full Text] [Related]
12. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
13. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
[TBL] [Abstract][Full Text] [Related]
14. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
Płotka A; Lewandowski K
Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
[TBL] [Abstract][Full Text] [Related]
17. A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript.
Mroczkowska A; Jaźwiec B; Urbańska-Rakus J; Szymanowska S; Tessmann A; Pająk S; Machnik K; Haus O; Wróbel T
BMC Med Genomics; 2022 Feb; 15(1):20. PubMed ID: 35123463
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report.
Ahmed IO; Ochogwu LO; Owojuyigbe TO; Akinola NO; Durosinmi MA
J Med Case Rep; 2021 Oct; 15(1):504. PubMed ID: 34625105
[TBL] [Abstract][Full Text] [Related]
19. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
Franca R; Kuzelicki NK; Sorio C; Toffoletti E; Montecchini O; Poropat A; Rabusin M; Curci D; Paladin D; Stocco G; Decorti G
Curr Med Chem; 2018; 25(24):2811-2825. PubMed ID: 28748759
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
